RT Journal Article
SR Electronic
T1 Latent tuberculosis infection (LTBI) treatment completion and complication in Leeds, UK
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP p2608
VO 38
IS Suppl 55
A1 Ahmed, Rizwan
A1 Arif, Mohammad
A1 Hopper, Daniel
A1 Mullarkey, Catherine
A1 Moffitt, Sandy
A1 Watson, John
YR 2011
UL https://publications.ersnet.org//content/38/Suppl_55/p2608.abstract
AB Background: Successful LTBI treatment (Rx) is essential in controlling TB in low incidence countries. Reported LTBI Rx completion rate in USA, Canada and UK is around 50% [1.2]. In Leeds we run an active screening programme for both new entrant and contact screening with a great emphasis on patient education and close follow-up.Methods: We conducted a retrospective review of all the LTBI patients (excluding those starting Rx pre anti-TNF) who were offered and accepted Rx in 2009 in Leeds. We looked at the completion rate, side effects (SE) of the Rx and reasons for not completing Rx.Results: 184 LTBI patients were offered and accepted Rx. 89% (163/184) of the patients successfully completed the Rx.View this table:Table 1Of those not completing the Rx 38% (8/21) had moved out of Leeds and another 38% (8/21) failed to follow up without known reason, only 3 patients stopped Rx due to SE.Conclusion: Good compliance is achievable with patient education and close follow-up. Treatment side effects of LTBI are usually mild and self resolving.References:1. Horsburgh C.R. Jr et al. Latent TB infection treatment acceptance and completion in the United States and Canada. Chest 2010;137(2):401-9.2. Rennie T.W. et al. Patient choice promotes adherence in preventive treatment for latent tuberculosis. Eur Respir J 2007;30:728-735.